| Autor: |
Kong, Amanda M., Pavilack, Melissa, Hairong Huo, Shenolikar, Rahul, Moynihan, Meghan, Marchlewicz, Elizabeth H., Chebili-Larson, Christina, Min, Stella, Subramaniam, Deepa S. |
| Rok vydání: |
2021 |
| DOI: |
10.6084/m9.figshare.14135068 |
| Popis: |
Non-small cell lung cancer (NSCLC) with brain metastases (BM) is difficult to treat and associated with poor survival. This study assessed the impact of BM on healthcare-related utilization and costs (HRUC) among patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Adults newly-diagnosed with metastatic NSCLC, initiating first-/second-generation EGFR-TKI treatment, with BM or no BM (NBM), were identified retrospectively from IBM MarketScan healthcare claims databases (2013–2017). HRUC were measured during the variable-length follow-up period. Generalized linear models assessed the impact of BM on total healthcare costs, standardized to 2017 US$. Overall, 222 BM and 280 NBM patients were included, with a mean duration of follow-up of 14 months. Adjusted NSCLC-related and all-cause costs over average follow-up were 1.2 times higher among BM patients (Δ$5,640 and Δ$6,366, respectively; p p p p =0.172) and outpatient ($2,443 vs $747, p p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
